Patently Wrong – The Jury’s Verdict In Apple v. Samsung 19/09/2012 by Intellectual Property Watch 4 Comments All is fair in love and (patent) war, but apparently not when it comes to awarding damages in patent litigation, writes South Africa’s Cobus Jooste.
America Invents Act: Another Piece Of Patent Reform Puzzle Falls Into Place 13/09/2012 by Liza Porteus Viana, Intellectual Property Watch Leave a Comment Another phase of historic patent reform goes into effect next week in the United States, as officials from the US Patent and Trademark Office tour the country, answering questions from stakeholders about forthcoming changes in patent law, thanks to the America Invents Act (AIA). The next batch of rules the USPTO is implementing for the AIA go into effect 16 September.
Novartis Challenge To India Patent Law Put Off To 11 September 22/08/2012 by Intellectual Property Watch Leave a Comment The Supreme Court of India today did not get to an agenda item involving a challenge to India’s patent law by Swiss pharmaceutical company Novartis, and it is now scheduled to come up on 11 September. The case is considered to have potential widespread impact on the production of lower priced generic medicines.
Health Advocates Eye Proposed Changes To Patent Law In South Africa 20/08/2012 by Linda Daniels for Intellectual Property Watch 4 Comments CAPE TOWN – South African health activists and pharmaceutical industry stakeholders are keeping close watch over the government’s attempts to amend patent laws, which activists claim compromise the ability of the country’s poor majority to access cheaper generic medicines.
Isolated DNA Declared Patentable By US Court Of Appeals 17/08/2012 by Intellectual Property Watch 4 Comments The United States Court of Appeals for the Federal Circuit released a decision today (16 August) on the patentability of genes in yet another twist to the so-called Myriad case. At stake was the patentability of two human genes associated with hereditary breast cancer and ovarian cancer. Myriad Genetics’ patents were challenged by the Association for Molecular Pathology.
A Look At India’s Key Pharmaceutical Patent Case 07/08/2012 by Intellectual Property Watch Leave a Comment This month, the Indian Supreme Court will hear final arguments in a challenge by the pharmaceutical company Novartis against the Indian Patent Office’s rejection of a patent for the leukemia drug, Glivec. The Court’s ruling will have profound implications for pharmaceutical patenting in India, and more generally how countries with newly introduced pharmaceutical patent regimes […]
Innovation And The Law: Some Lessons From The Patent Wars 27/07/2012 by Steven Seidenberg for Intellectual Property Watch 3 Comments They’ve been at each other’s throats for three years, and there’s no end in sight. Over two dozen businesses involved with smartphones and tablet computers are suing one another for patent infringement in numerous lawsuits around the world. These patent wars have cost the companies billions of dollars, clogged the courts, and prevented consumers from buying some devices they want with features they prefer. Is this really the best way to promote innovation and competition?
Novartis’ Indian Patent Law Challenge Postponed Again 06/07/2012 by Intellectual Property Watch Leave a Comment The Supreme Court of India has postponed hearing final arguments in a key challenge to India’s patent law brought by Swiss pharmaceutical company Novartis.
ITU To Hold High-Level Talks On “Innovation-Stifling, Rampant” Patent Litigation 06/07/2012 by William New, Intellectual Property Watch Leave a Comment The UN International Telecommunication Union (ITU) today announced it will hold a high-level meeting on the global surge in standards-related patent litigation which it said is stifling innovation in information and communications technology.
Europe Reaches Agreement On Unitary Patent 29/06/2012 by William New, Intellectual Property Watch 8 Comments After years of at times embarrassing political and procedural wrangling, members of the European Union today agreed to create a single patent system for 25 EU member states, including a unified patent court split between Paris, Munich and London. The decision also contains a copyright element.